Get the Stockscreener App
0.7178
8.82%
-0.0694
Pharmacyte Biotech Inc stock is traded at $0.7178, with a volume of 205.27K.
It is down -8.82% in the last 24 hours and down -5.55% over the past month.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
See More
Previous Close:
$0.7872
Open:
$0.78
24h Volume:
205.27K
Relative Volume:
1.05
Market Cap:
$7.71M
Revenue:
-
Net Income/Loss:
$-3.28M
P/E Ratio:
-0.6898
EPS:
-1.0406
Net Cash Flow:
$-4.80M
1W Performance:
-4.31%
1M Performance:
-5.55%
6M Performance:
-14.56%
1Y Performance:
-32.28%
1-Day Range:
$0.7178
$0.8007
1-Week Range:
$0.7178
$0.84
52-Week Range:
$0.63
$1.51
Pharmacyte Biotech Inc Stock (PMCB) Company Profile
Name
Pharmacyte Biotech Inc
Sector
Industry
Phone
(917) 595.2850
Address
3960 HOWARD HUGHES PARKWAY, LAS VEGAS
Compare PMCB vs MOBBW, SHMD, GOODO, PSNYW, DWLD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 2.24 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
2.38 | 3.16B | 0 | 0 | 0 | 0.00 |
SHMD
Schmid Group N V
|
6.54 | 425.01M | 52.15M | -21.46M | 0 | -0.4675 |
GOODO
Gladstone Commercial Corporation
|
20.26 | 372.90M | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
2.909 | 269.09M | 2.07B | -1.42B | -1.37B | -0.6765 |
DWLD
Davis Select Worldwide ETF
|
46.61 | 0 | 0 | 0 | 0 | 0.00 |
Pharmacyte Biotech Inc Stock (PMCB) Latest News
PharmaCyte Biotech Inc (PMCB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
PharmaCyte Biotech Inc (PMCB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
PharmaCyte Biotech Inc (PMCB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
PharmaCyte Biotech (PMCB) Holds Steady at $0.7: Consolidation Near Key SupportVolume Profile - newsline.com
PMCB Technical Analysis & Stock Price Forecast - Intellectia AI
PMCB Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
PharmaCyte Biotech Inc. (PMCB) Q1 2026 Earnings: Pre‑Revenue Biotech Reports Loss, Shares Slide 3.5%Earnings Surprise Stocks - newsline.com
Tranche Update on PharmaCyte Biotech, Inc.'s Equity Buyback Plan announced on February 2, 2023. - marketscreener.com
PharmaCyte Biotech (PMCB) Rises 3.19%: Approaching Resistance Zone Amid Biotech Sector FocusChaikin Flow - newsline.com
PharmaCyte Biotech (PMCB) Slips 3.3% as Stock Nears Critical Support at $0.79ETF NAV Deviation - newsline.com
PharmaCyte Biotech (PMCB) Jumps 12.76% as Biotech Speculation Heats UpBuyback Factor - The Legal Advocate
PharmaCyte Biotech (PMCB) Edges Higher: Support-Holding Action at $0.81IPO Entry Watch - Newser
PMCB Q1 2026 Earnings: Pre-Revenue Biotech Reports Negative EPS; Stock Rises on Potential Pipeline Progress - Newser
PharmaCyte Biotech Inc. (PMCB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
PharmaCyte Biotech (PMCB) Rallies 5.6% as Biotech Sentiment ImprovesNHNL Divergence - Newser
PharmaCyte Biotech (PMCB) Q1 2026 Earnings: Narrowing Loss Amid Strategic Pipeline ProgressHigh Estimate Range - Newser
PharmaCyte Biotech Inc. (PMCB) Q1 2026 Earnings: Pre-Revenue Biotech Reports Wider Loss Amid Strategic Pipeline ProgressShared Momentum Picks - Newser
PharmaCyte Biotech (PMCB) Q1 2026 Earnings: Revenue $N/A, Matching ViewsGuidance Revision Trend - Newser
TradingKey - TradingKey
PharmaCyte Biotech (PMCB) Stock: Buy or Sell |Risk Report - newser.com
PMCB SEC FilingsPharmacyte Biotech Inc 10-K, 10-Q, 8-K Forms - Stock Titan
PMCB Stock Jumps 25% After Company Sells Stake In Femasys - MSN
PharmaCyte Biotech (PMCB) Stock Take Profit (Gains) 2026-04-20Risk Reward Setups - newsline.com
Aug Intraday: Is PharmaCyte Biotech Inc a good ESG investment2026 Short Interest & Accurate Trade Setup Notifications - baoquankhu1.vn
PharmaCyte Biotech Operating Margin | PMCB - MLQ.ai
EV Market: Should I invest in PharmaCyte Biotech Inc before earningsJobs Report & Weekly High Return Opportunities - baoquankhu1.vn
How liquid is PharmaCyte Biotech Inc stockPortfolio Performance Report & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Is PharmaCyte Biotech (PMCB) Stock Near Support | Price at $0.69, Up 5.96%New Highs New Lows - newsline.com
Aug Ideas: What is the Moat Score of PharmaCyte Biotech Inc2026 EndofYear Setup & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Is PharmaCyte Biotech Inc vulnerable to short sellersMarket Sentiment Report & Growth Focused Stock Pick Reports - baoquankhu1.vn
PharmaCyte Biotech Shareholders Approve Governance and Equity Actions - The Globe and Mail
Director Weinstein receives 119,170 stock options at PharmaCyte Biotech (PMCB) - Stock Titan
Director at PharmaCyte Biotech (PMCB) gets 119,170 options - Stock Titan
PharmaCyte Biotech (PMCB) director awarded 119,170 stock options at $0.67 - Stock Titan
PharmaCyte Biotech (PMCB) director receives 119,170 stock options at $0.67 - Stock Titan
PharmaCyte Biotech (PMCB) wins approval for reverse split range and 2M new plan shares - Stock Titan
PMCB Stock Chart | PHARMACYTE BIOTECH INC (NASDAQ:PMCB) - ChartMill
Insider Sell: How liquid is PharmaCyte Biotech Inc stock2026 Setups & Safe Entry Momentum Tips - baoquankhu1.vn
PharmaCyte Biotech, Inc. (PMCB) Q3 2026 10-Q Report: Financial Results, Stock Information, and SEC Filings - Minichart
PharmaCyte Biotech (PMCB) logs neutral Form 4 as 10% FEMASYS (FEMY) owner - Stock Titan
PharmaCyte Biotech (FEMY) reports 7.87% stake including warrants - Stock Titan
PharmaCyte Biotech 10-Q: $0.0M Revenue, $(0.17) EPS (Q3), $(2.41) EPS (YTD) - TradingView
PharmaCyte Biotech (NASDAQ: PMCB) details Jan 2026 results and cash runway - Stock Titan
PharmaCyte Biotech delays quarterly report filing - MSN
Analyzing Prime Medicine (NYSE:PRME) & PharmaCyte Biotech (OTCMKTS:PMCBD) - Defense World
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
PharmaCyte Biotech (PMCB) seeks reverse split, equity plan boost at 2026 meeting - Stock Titan
Pharmacyte Biotech Inc Stock (PMCB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):